Does Priority Review Change The Bull Case For Intellia Therapeutics Stock (NTLA)?
- Intellia Therapeutics reported that the FDA previously accepted its Biologics License Application for lonvo-z in hereditary angioedema and granted the gene editing therapy Priority Review, with no advisory committee planned. This reflects the regulator’s comfort with the submitted Phase 3 package and existing global designations.
- This regulatory progress moves Intellia Therapeutics closer to potential commercialization of an in vivo CRISPR treatment. This development could reshape its revenue mix, operating cost profile, and reliance on partnerships once pricing, reimbursement, and real world use patterns become clear.
- We will now examine how Intellia Therapeutics’ investment narrative could shift given lonvo-z’s Priority Review status…
Source link
